Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Wen. Jimmy J; Nadora. Denise D; Bernstein. Ethan E; How-Volkman. Christiane C; Truong. Alina A; Joy. Bethany B; Kou. Megan M; Muttalib. Zohaer Z; Alam. Arsh A; Frezza. Eldo E
Key Findings
- GLP‑1 receptor agonists as a class showed a 44% higher relative risk of pancreatitis (RR = 1.44), but this was not significant when analyzed by background medication use.
- No overall increase in pancreatic cancer risk was found (RR = 1.30), with a slight rise only in participants taking other medications (RR = 1.85).
- Retatrutide was included among the studied agents, so its safety profile aligns with the broader GLP‑1 RA class regarding these rare adverse events.
Practical Outcomes
- For biohackers considering retatrutide or similar GLP‑1 drugs, the main takeaway is to stay alert for pancreatitis symptoms (abdominal pain, nausea) especially if you’re on other meds that affect the pancreas. Regular monitoring (e.g., periodic lipase checks) can help catch issues early. The data do not suggest a major cancer risk, but a cautious approach is wise when combining these agents with other treatments.
Summary
A big review of 62 trials looked at whether drugs that act like GLP‑1 (including the newer peptide retatrutide) raise the chances of getting pancreatitis or pancreatic cancer. Overall, there was a modest rise in pancreatitis risk, but this disappeared when the data were split by whether people were also taking other medicines. The chance of pancreatic cancer didn’t go up overall, though a small increase showed up in the subgroup that used background meds.
Abstract
This meta-analysis evaluates the rates of pancreatitis/pancreatic cancer among glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in randomised controlled trials (RCTs). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase, and Cochrane Library for GLP-1 RA RCTs that evaluated pancreatitis/pancreatic cancer. A meta-analysis was conducted to evaluate this risk; subgroup analysis was performed with and without background medications. 62 studies utilising dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, or tirzepatide, with 66,232 patients, mean age of 58.3 years (14.4 to 68), and mean follow-up of 43.5 weeks (1 to 198) were included in this study. Meta-analysis showed a significantly increased risk of pancreatitis (RR: 1.44, 95% CI 1.09-1.89, p = 0.009), but not when stratified by background medications (RR: 1.28, 95% CI 0.87-1.87) and without background medications (RR: 1.37, 95% CI 0.91-2.05). Pancreatic cancer and GLP-1 RA use showed no significant association (RR: 1.30, 95% CI 0.86-1.97). However, a significant increase was found with background medications (RR: 1.85, 95% CI 1.05-3.26, p = 0.03), but not without (RR: 0.81, 95% CI 0.43-1.55). GLP-1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use. Overall risk for pancreatic cancer was not observed, but a slight association was found when stratified with background medications. However, this difference is likely minimal, given the numerous studies excluded from the meta-analysis where both treatment arms had zero events.
Study Information
pubmed
2025
2025-09-01T00:00:00.000Z
10.1002/edm2.70113
1
17